ReviewImmunology2007
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
Review in Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 76 citations in OpenAlex.
- Integration of multi-source gene interaction networks and omics data with graph attention networks to identify novel disease genes.Bioinformatics (Oxford, England) · 2025Article
- Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid.Computers in biology and medicine · 2022Article
- Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis.Acta pharmaceutica Sinica. B · 2022Review
- Ghrelin protects against lipopolysaccharide-induced acute respiratory distress syndrome through the PI3K/AKT pathway.The Journal of biological chemistry · 2021Article
- New Pharmacological Tools to Target Leukocyte Trafficking in Lung Disease.Frontiers in immunology · 2021Review
- Phosphoproteome profiling provides insight into the mechanisms of ventilator-induced lung injury.Experimental and therapeutic medicine · 2020Article
- Subacute TGFβ Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway.American journal of respiratory cell and molecular biology · 2020Article
- Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.Nature communications · 2018Article
- Article
- TGFβ as a therapeutic target in cystic fibrosis.Expert opinion on therapeutic targets · 2018Review
- Lignans Isolated From Flower Buds ofFrontiers in pharmacology · 2018Article
- Lung injury after simulated cardiopulmonary bypass in an isolated perfused rat lung preparation: Role of mitogen-activated protein kinase/Akt signaling and the effects of theophylline.The Journal of thoracic and cardiovascular surgery · 2014Article
- FIZZ1 promotes airway remodeling through the PI3K/Akt signaling pathway in asthma.Experimental and therapeutic medicine · 2014Article
- Article
- PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice.Neuroscience · 2013Article
- New anti-inflammatory targets for chronic obstructive pulmonary disease.Nature reviews. Drug discovery · 2013Review
- Inflammatory signalings involved in airway and pulmonary diseases.Mediators of inflammation · 2013Review
- Review
- PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses.Journal of clinical immunology · 2012Article
- PI3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model.Inflammation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The family of lipid kinases termed phosphoinositide-3-kinase (PI3K) is known to contribute at multiple levels to innate and adaptive immune responses, and is hence an attractive target for drug discovery in inflammatory and autoimmune disease, including respiratory diseases. The development of isoform-selective pharmacological inhibitors, targeted gene manipulation and short interfering RNA (siRNA) target validation have facilitated a better understanding of the role that each member of this family of kinases plays in the physiology and pathology of the respiratory system. In this review, we will evaluate the evidence for the roles of specific PI3K isoforms in the lung and airways, and discuss their potential as targets for novel drug therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.